PCRT provides a central resource to biotech and pharma companies seeking strategies and clinical resources. Our comprehensive approach to clinical trial design and implementation includes:
PCRT has created a multi-center Serum and DNA Repository for the discovery of biomarkers for this disease. The PCRT developed a clinical study designed to collect blood from people with pancreatic cancer, pancreatitis, liver disease, and from healthy and at-risk volunteers in order to identify biomarkers for early diagnosis and treatment of pancreatic cancer. The samples are stored in a central repository or bank as a resource for current and future scientific studies. PCRT researchers use the samples to identify new biomarkers for early diagnosis, disease stage, natural history of the disease, response to treatment and to identify possible therapeutic interventions.
In order to better understand this disease, the PCRT would like to expand this repository to collect tissue and images taken of current pancreatic cancer patients receiving treatment and use this data to discover how effectively current treatments work, and how to develop NEW treatments for pancreatic cancer patients at all stages of disease. We also want to use this very important data to identify biomarkers or changes in tissue (seen on a CT or PET scan) that might indicate early the onset of pancreatic cancer.